

Native Influenza B Virus Tokio 53/99

| | | | |
|--------------------|-----------|------------------|--------|
| Catalog No. | CSI15854A | Quantity: | 10 µg |
| | CSI15854B | | 50 µg |
| | CSI15854C | | 1.0 mg |

Description: Influenza-B virus is a genus in the virus family Orthomyxoviridae. The only species in this genus is called "Influenza B virus". Influenza B virus only infects humans and seals. This limited host range is apparently in contrast with those caused by the similar Influenza virus Aas both mutate by both genetic drift and reassortment. Influenza-B virus evolves slower than A viruses and faster than C viruses. Influenza-B virus mutates at a rate 2-3 times lower than type A. However, influenza B mutates enough that lasting immunity is not possible. The Influenza B virus capsid is enveloped while its virion consists of a matrix protein + envelope + nucleoprotein complex + nucleocapsid, and a polymerase complex. Influenza B is sometimes spherical and sometimes filamentous. Its 500 or so surface projections are made of hemagglutinin and neuraminidase. The Influenza B virus is 14648 nucleotides long and consists of eight segments of linear negative-sense, single-stranded RNA. The multipartite genome is encapsidated, each segment in a separate nucleocapsid, and the nucleocapsids are surrounded by one envelope. Allantoic fluid of 10 days old embryonated eggs, inoculated with influenza B virus, strain B/Tokio/53/99. The Influenza B Virus was purified by Ultra centrifugation with 10-40% sucrose gradient.

Physical Appearance: Sterile Filtered colorless solution

Source: Allantoic fluid

Formulation: The B/Tokio/53/99 solution contains 0.1M NaCl + 10mM Tris Hcl + 1mM EDTA pH-8 + 0.1 % sodium azide (NaN₃) and 0.005 % thimerosal.

Precaution: Sodium azide is a poisonous and hazardous substance which should be handled by trained staff only. **Precaution:** Thiomersal is a poisonous and hazardous substance which should be handled by trained staff only.

Purity: Greater than 90.0% as determined by Analysis by SDS-PAGE.

Inactivation: Thimerosal and beta propiolactone treatment
This product has been treated in a manner consistent with methods of inactivation. Generally accepted good laboratory practices appropriate to microbiological/viral safe handling practices and techniques are required at work.

Immunological Activity: Serological studies of influenza B virus, immunogen for antibody production. Tested with anti-influenza B monoclonal antibodies in ELISA.

Storage & Stability: B/Tokio/53/99 although stable 4°C for 4 weeks, should be stored desiccated below -18° C.
Please prevent freeze-thaw cycles.

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.